Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March, 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Healthinote is a smartphone-based toolkit designed to boost patient engagement by providing personalised, trustworthy, and ...

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...